This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Stocks With High Net Income Ratio to Grab Now
by Nitish Marwah
Investors always have a keen eye for companies having a high level of profitability regardless of the market condition.
Zacks.com featured highlights include: B2Gold, Burlington Stores, FibroGen, Matrix Service Company and Great Lakes Dredge & Dock
by Zacks Equity Research
Zacks.com featured highlights include: B2Gold, Burlington Stores, FibroGen, Matrix Service Company and Great Lakes Dredge & Dock
5 Stocks With High Net Income Ratio to Scoop Up
by Nitish Marwah
Profitability analysis is one of the best ways to evaluate the prospects of a company. It is used in detecting a profitable company over a loss-making one.
FibroGen Enters Oversold Territory
by Zacks Equity Research
FibroGen, Inc. (FGEN) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.2%
by Zacks Equity Research
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia
by Zacks Equity Research
FibroGen (FGEN) doses the first patient in a phase II study on roxadustat for the treatment of anemia in cancer patients receiving chemotherapy.
Tyme Initiates Pivotal Stage of Pancreatic Cancer Study
by Zacks Equity Research
Tyme (TYME) initiates the pivotal stage of the TYME-88-Panc study evaluating oral SM-88 (racemetyrosine) for third-line treatment of patients with metastatic pancreatic cancer.
BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors
by Zacks Equity Research
BioLineRx (BLRX) starts dosing the first patient in the part 2 of the phase I/IIa study evaluating AGI-134 for solid tumors.
Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8%
by Zacks Equity Research
Dova Pharmaceuticals (DOVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa
by Zacks Equity Research
The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs
by Zacks Equity Research
Zoetis' (ZTS) leading animal health portfolio gets a boost with the approval of Simparica Trio.
FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD
by Zacks Equity Research
FibroGen's (FGEN) Evrenzo (roxadustat) wins a marketing approval in Japan for treating anemia caused by chronic kidney disease in dialysis-dependent patients.
Zacks.com featured highlights include: ACM, FibroGen, Funko, Matrix Service and PetIQ
by Zacks Equity Research
Zacks.com featured highlights include: ACM, FibroGen, Funko, Matrix Service and PetIQ
What Makes Crinetics Pharmaceuticals (CRNX) a Strong Sell?
by Zacks Equity Research
Crinetics Pharmaceuticals (CRNX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
5 Stocks with High Net Income Ratio to Grab Now
by Nitish Marwah
Investors always have a keen eye for companies having a high level of profitability regardless of the market condition.
Theravance Announces Positive Early Data on JAK Inhibitor
by Zacks Equity Research
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised)
by Zacks Equity Research
Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.
Endo International Files BLA for Label Expansion of Xiaflex
by Zacks Equity Research
Endo International (ENDP) files BLA for the additional indication of Xiaflex [collagenase clostridium histolyticum (CCH)] for the treatment of cellulite in the buttocks.
Radius (RDUS) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
Radius (RDUS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Ensign Group to Spin Off Home Health & Hospice Business
by Zacks Equity Research
Ensign Group (ENSG) to separate its home health and hospice business from the parent company.
FibroGen (FGEN) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
FibroGen (FGEN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
by Zacks Equity Research
AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dependent patients.
Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta
by Zacks Equity Research
The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.
Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4
by Zacks Equity Research
Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.
Tilray (TLRY) Catches Eye: Stock Jumps 8.4%
by Zacks Equity Research
Tilray (TLRY) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.